Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Decentralized Clinical Trials Among Topics Slated For CDER Guidance In 2020

Feb 03 2020

• By Brenda Sandburg

Vintage hourglass on yellow background with to do list in 2020 text. — FDA issues list of guidances it plans to publish this year

Related Content

Orphan Exclusivity For Gene Therapies Hinges On Two Big Factors

Jan 29 2020

US FDA's Decade In Review: From Biosimilars To Real-World Evidence

Jan 15 2020

Pediatric Studies: Industry Seeks Narrower, More Timely Requests From US FDA

Jan 06 2020

Disease-Specific Drug Development Guidances Coming From US FDA In 2018

Jan 19 2018

Genomics Data Should Get More Attention In FDA Drug Review And Labeling, Regeneron Says

Dec 02 2019

Clinical Trial Reform Is A Focus For CDER's 2019 Guidance Agenda

Mar 14 2019

NEJM Takes Aim At Expensive Accelerated Approval Drugs Amid Congressional Drug Pricing Debate

May 25 2017

Drug Sponsors Are On Schedule With Most Post-Approval Studies

Nov 18 2018

Related Companies

Regeneron Pharmaceuticals, Inc.

Additional Topics

United States Guidance Documents Generic Drugs Clinical Trials Policy Regulation BioPharmaceutical Pink Sheet Perspectives

More from Generics

More from Biosimilars & Generics

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window